Cerebral Amyloid Angiopathy (CAA) is a cerebrovascular pathology characterized by the accumulation of amyloid-beta (Aβ) peptides in the walls of small to medium-sized blood vessels in the brain[1]. This mechanism page explores how CAA contributes to neurodegenerative processes, particularly in Alzheimer's disease and related dementias.
CAA represents a critical intersection between vascular pathology and neurodegeneration, accounting for both hemorrhagic stroke risk and vascular contributions to cognitive decline[2]. Understanding CAA mechanisms is essential for developing therapeutic strategies that target the vascular component of neurodegenerative diseases.
CAA involves the progressive deposition of amyloid-beta peptides, predominantly Aβ40, in the media and adventitia of leptomeningeal and cortical blood vessels[3]. This vascular amyloid accumulation differs fundamentally from the parenchymal plaque formation seen in Alzheimer's disease.
Key Pathological Features:
Vascular amyloid localization: Deposits primarily affect:
Aβ40 predominance: While Aβ42 is more aggregation-prone and forms parenchymal plaques, Aβ40 shows higher affinity for cerebral vessel walls due to its greater solubility and ability to travel further from production sites[4]
Vascular wall transformation: Amyloid deposition replaces smooth muscle cells in the media layer, leading to:
The brain's waste clearance system relies heavily on perivascular pathways that drain Aβ along the basement membranes of cerebral blood vessels[5]. Several factors impair this drainage in CAA:
CAA is closely associated with blood-brain barrier (BBB) disruption[7]:
CAA and Alzheimer's disease share common pathogenic mechanisms but represent distinct pathological entities with significant overlap[8].
| Mechanism | Alzheimer's Disease | Cerebral Amyloid Angiopathy |
|---|---|---|
| Aβ production | ↑ APP processing | ↑ APP processing |
| Aβ accumulation | Parenchymal plaques | Vascular deposits |
| APOE4 risk | Strong risk factor | Strong risk factor |
| Vascular dysfunction | Secondary contribution | Primary pathology |
| Cognitive impact | Neuronal loss | Vascular injury |
CAA contributes to cognitive decline through multiple pathways[9]:
The vascular contributions of CAA to dementia include:
| Cell Type | Role in CAA Pathogenesis | Key Markers |
|---|---|---|
| Vascular smooth muscle cells | Aβ production, degeneration | α-SMA, SM22α |
| Endothelial cells | BBB dysfunction, transport | CD31, VE-cadherin |
| Pericytes | Perivascular clearance loss | PDGFRβ, NG2 |
| Astrocytes | Aβ clearance via LRP1 | GFAP, AQP4 |
| Microglia | Vascular inflammation | IBA1, CD68 |
The Boston Criteria v2.0 provides standardized diagnostic guidelines[10]:
Definite CAA:
Probable CAA with supporting pathology:
Probable CAA:
Possible CAA:
MRI Findings:
| Finding | Clinical Significance |
|---|---|
| Lobar microbleeds (GRE/SWI) | Primary diagnostic marker |
| White matter hyperintensities (FLAIR) | Chronic hypoperfusion |
| Cortical superficial siderosis | Recurrent hemorrhages |
| Dilated perivascular spaces | Drainage impairment |
| Cortical microinfarcts | Ischemic injury |
PET Imaging:
Anti-amyloid immunotherapies:
Vascular protective strategies:
Emerging targets:
Recent and ongoing CAA clinical trials focus on:
Van Veluw et al. Cerebral amyloid angiopathy (2020). 2020. ↩︎
Charidimou et al. Emerging concepts in sporadic CAA (2022). 2022. ↩︎
Gregg et al. Vascular dysfunction in CAA (2020). 2020. ↩︎
Herzig et al. Aβ40 in CAA (2009). 2009. ↩︎
Iliff et al. Perivascular drainage (2013). 2013. ↩︎
Friedman et al. APOE and CAA (2021). 2021. ↩︎
Montagne et al. BBB dysfunction in CAA (2022). 2022. ↩︎
Jäkel et al. CAA and AD relationship (2022). 2022. ↩︎
Smith et al. Vascular contributions to dementia (2020). 2020. ↩︎
Charidimou et al. Boston Criteria v2.0 (2022). 2022. ↩︎
Evin et al. BACE1 and CAA (2022). 2022. ↩︎
Yamada et al. APOE4 and CAA hemorrhages (2021). 2021. ↩︎